Guardant Health (GH) said Monday it launched its its molecular profiling test Guardant360 Tissue, which provides "a more complete view of cancer."
The tumor tissue test incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, the company said.
The test is covered by Medicare for eligible patients, the company said.
Price: 47.75, Change: -0.55, Percent Change: -1.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.